MTOR and mucositis: Although both chemotherapy and radiotherapy can lead to the formation of oral mucositis, patients treated with mammalian target of rapamycin (mTOR) inhibitors, such as everolimus, are especially vulnerable to mucositis (73.4% of patients, with over 30% of those being severe cases) [4].